Benzathine analogs
A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R 1 -R 10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R 3 or R 8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
1. A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of formula II:
wherein X is an optionally-substituted alkanediyl,
R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 9 and R 10 are each individually hydrogen, alkyl, halogen, amino, or hydroxy, and R 3 and R 8 are each a 6-membered N-heterocycle.
2. The compound of claim 1 , wherein the 6-membered N-heterocycle is selected from pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or triazinyl.
3. The compound of claim 1 , wherein X is an alkanediyl having a structure of —C n H 2n — wherein n is 2 to 5.
4. The compound of claim 3 , wherein X is —CH 2 —CH 2 —.
5. The compound of claim 1 , wherein the compound is selected from:
6. A pharmaceutical composition comprising at least one compound of claim 1 and at least one pharmaceutically acceptable additive.
7. A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:
8. The compound of claim 1 , wherein the 6-membered N-heterocycle is pyrimidinyl.
9. The compound of claim 1 , wherein X is an alkanediyl having a structure of —C n H 2n — wherein n is 2 to 5, and the 6-membered N-heterocycle is pyrimidinyl.
10. A pharmaceutical composition comprising the compound of claim 7 and at least one pharmaceutically acceptable additive.